David Heigener reports from the IASLC 20th WCLC symposium

(2:)

David Heigener introduces a new pathway tool for Europe designed to help clinicians

(1:1econd)

ASCO 2017 - David Heigener Interview Part 1

(1:42)

ASCO 2017 - David Heigener Interview Part 2

(1:37)

David Heigener reports from the IASLC 20th WCLC symposium

(1:50)

David Heigener presents for a symposium at IASLC 20th WCLC 2019

(58)

WCLC 2019: David Heigener discussing clinical trials in second-line treatment

(2:11)

Scientist Stories: David Schaffer, Engineering Viruses for Gene Therapy

(53:51)

Anti-Angiogenesis - Antiangiogenesis

(2:26)

Cancer Immune Checkpoint Inhibitors

(5:33)

Scientist Stories: Dave Schaffer, Pioneer in Bioengineering and Gene Therapies

(54:18)

Has Human Evolution Stopped?

(43:14)

How Does Antiangiogenic Therapy Work?

(6:11)

How does cancer immunotherapy work?

(3:7)

I Swear

(5:17)

How to set the tension on your Heiniger Clippers

(1:28)

WCLC 2019: David Heigener discussing anti-angiogenic vs immune checkpoint inhibitor

(1:1econd)

WCLC 2019: David Heigener discussing clinical trials in second-line treatment (2)

(2:12)

WCLC 2019: David Heigener discussing 'My personal approach to second-line treatment in 2019'

(1:55)

WCLC 2019: David Heigener discussing future perspectives in second-line NSCLC treatment

(2:)

ESC TV 2014 - Who is funding cardiovascular research?

(4:23)

Overcoming resistance to IO with sitravatinib + tocilizumab in patients with lung cancer

(2:53)

TGen's COVID-19 Update Episode 4

(2:31)

Discovery Matters | Ep74. Patient-derived organoids (part 1)

(23:7)

NSCLC: Mechanisms of Resistance to Antiangiogenic Therapy

(3:)

COVID-19 Webinar [Clip]: Why We Can't Rely on Antibody Testing to Reboot the U.S. Economy

(28)

Panel Presentation: Understanding iRAEs from Immune Checkpoint Inhibitors

(5:24)

Upfront Immunotherapy for PD-L1+ NSCLC

(8:44)

Combined Immunotherapy and Chemotherapy for NSCLC

(5:27)